In a Canadian dispute for an antiviral product, CRA was retained to evaluate lost unit sales and lost profits suffered by a branded company from the allegedly improper sale of generic product in violation of a settlement agreement. At issue was the impact of the generic manufacturer flooding the market with product for a brief window of time before removing its product from the market and the effect on branded sales over time.
Richard Bergin joins CRA's Finance Practice as Vice President
CRA is pleased to announce that Richard Bergin has joined the company’s Finance Practice as a vice president. “We are very pleased to welcome Richard to CRA,”...